| scholarly article | Q13442814 |
| P356 | DOI | 10.3171/PED.2006.105.5.418 |
| P698 | PubMed publication ID | 17328268 |
| P2093 | author name string | Children's Oncology Group | |
| C David James | |||
| Ronald L Hamilton | |||
| Ian F Pollack | |||
| Allan J Yates | |||
| Jonathan L Finlay | |||
| Tianni Zhou | |||
| Emiko J Holmes | |||
| Sydney D Finkelstein | |||
| Judith Burnham | |||
| P433 | issue | 5 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 418-424 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Journal of Neurosurgery | Q15708886 |
| P1476 | title | Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort | |
| P478 | volume | 105 |
| Q64227444 | A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation |
| Q48095585 | A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. |
| Q34722457 | A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium |
| Q34196216 | Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group |
| Q36844744 | Biologically targeted therapeutics in pediatric brain tumors |
| Q99237709 | CAR T Cell Therapy for Pediatric Brain Tumors |
| Q35799783 | Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models |
| Q33970971 | Childhood brain tumors: epidemiology, current management and future directions |
| Q36048214 | Clinical and molecular characteristics of congenital glioblastoma |
| Q90448649 | Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children |
| Q36356194 | Combination genetic signature stratifies lower-grade gliomas better than histological grade |
| Q91990361 | Congenital glioblastoma multiforme with long-term childhood survival: a case report and systematic review |
| Q36001219 | Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy |
| Q35996276 | Deregulation of ion channel and transporter encoding genes in pediatric gliomas |
| Q92445464 | Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas |
| Q33861173 | Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma |
| Q34221722 | Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. |
| Q37190159 | Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas. |
| Q35235702 | EGFR expression stratifies oligodendroglioma behavior |
| Q38471174 | Gene expression analyses to explore the biomarkers and therapeutic targets for gliomas |
| Q37838362 | Genetic modeling of gliomas in mice: new tools to tackle old problems |
| Q40950711 | Genome-wide copy number analysis in pediatric glioblastoma multiforme |
| Q34132699 | Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas |
| Q45343976 | Gliomas in children |
| Q35183137 | Histologically proven, low-grade brainstem gliomas in children: 30-year experience with long-term follow-up at Mayo Clinic |
| Q34458930 | IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group |
| Q48716816 | Impact of molecular biology studies on the understanding of brain tumors in childhood |
| Q35070545 | Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. |
| Q42066665 | Innate neural stem cell heterogeneity determines the patterning of glioma formation in children |
| Q34480582 | Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors |
| Q33990951 | Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease |
| Q89880080 | Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme |
| Q34565801 | Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group |
| Q41843698 | Modeling Adult Gliomas Using RCAS/t-va Technology |
| Q26785952 | Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment |
| Q38359284 | Molecular biology of pediatric brain tumors and impact on novel therapies |
| Q55178627 | Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. |
| Q37238690 | Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas |
| Q39943645 | Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. |
| Q38873292 | Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials. |
| Q35068192 | PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. |
| Q36179171 | PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome |
| Q37729676 | Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge |
| Q38074094 | Paediatric spinal glioblastoma: case report and review of therapeutic strategies |
| Q37213305 | Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities |
| Q37284256 | Pediatric glioblastomas: a histopathological and molecular genetic study |
| Q36644898 | Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy |
| Q39208269 | Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. |
| Q51103541 | Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology. |
| Q38074880 | Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies |
| Q34359662 | Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma |
| Q37069238 | Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. |
| Q37689492 | Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas |
| Q33825938 | Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas |
| Q38203283 | Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment |
| Q34191508 | Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas |
| Q43238974 | Something old and something new about molecular diagnostics in gliomas |
| Q36800148 | Targeted therapy for BRAFV600E malignant astrocytoma. |
| Q34722440 | Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group |
| Q39805300 | The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro |
| Q38248990 | The genetic signatures of pediatric high-grade glioma: no longer a one-act play |
| Q28070264 | The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors |
| Q37904503 | Treatment of high-grade glioma in children and adolescents |
| Q38032269 | What to do when there is no standard of care: A brief review of treatment options for glioblastoma in children |
Search more.